Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: Identification of a two-gene prognostic model associated with cytolytic activity for colon cancer

Fig. 7

The immune signature predicts immunotherapeutic benefits. a, c Correlation between CYT with CD274 (PD-L1), CTLA4, LAG3, PDCD1 (PD1) and TIGIT expression in the TCGA cohort and GSE39582. b, d Correlation between risk score and CD274 (PD-L1), CTLA4, LAG3, PDCD1 (PD1) and TIGIT expression in the TCGA cohort and GSE39582. e Comparison of the Tumour Immune Dysfunction and Exclusion (TIDE) prediction scores in the low- and high-risk score groups in the TCGA cohort. f Immunotherapeutic responses to anti-CTLA-4 and -PD-1 treatments in high- and low-risk patients

Back to article page